The role of neoadjuvant HER2-targeted therapies in HER2-overexpressing breast cancers

J. Lemieux MSc MD, M. Clemons MB BS MD,† L. Provencher MD MA,† S. Dent BSc MD,§ J. Latreille MD,† J. Mackey MD,‡ K.I. Pritchard MD,** D. Rayson MD,†† Sh. Verma MD,§ Su. Verma MSEd MD,** B. Wang MSc,‡‡ and S. Chia MD§§

ABSTRACT

Women receiving neoadjuvant systemic therapy for primary operable or inoperable breast cancer can potentially benefit in a number of ways, but the main advantage, which has been consistently demonstrated, is improved tumour resectability. Given the improvement in outcomes with the adjuvant use of trastuzumab in patients with early-stage breast cancer positive for the human epidermal growth factor receptor 2 (HER2), questions have been raised about the use of trastuzumab in the neoadjuvant setting. The present paper reviews the currently available data and outlines suggestions from a panel of Canadian oncologists about the use of trastuzumab and other HER2-targeted agents in the neoadjuvant setting.

The panel focussed on

• the use of trastuzumab and other HER2-targeted agents as neoadjuvant therapy in primary operable, locally advanced, and inflammatory breast cancer; and
• possible choices of chemotherapeutic regimens with trastuzumab.

The suggestions described here will continue to evolve as data from current and future trials with trastuzumab and other HER2-targeted agents emerge.

KEY WORDS

Neoadjuvant, breast cancer, HER2-targeted therapy, trastuzumab

1. INTRODUCTION

Chemotherapy produces similar survival gains whether given in the neoadjuvant or the adjuvant setting. A meta-analysis of randomized trials comparing neoadjuvant with adjuvant chemotherapy found no difference in distant disease recurrence [risk ratio (RR): 0.94; 95% confidence interval (CI): 0.83 to 1.06] or overall survival rate (RR: 1.00; 95% CI: 0.90 to 1.12). Notably, however, most of the patients in the relevant trials had operable cancer at randomization.

In the clinical setting, neoadjuvant therapy has several potential advantages over standard adjuvant therapy. First, for operable tumours, the use of neoadjuvant therapy increases the rate of breast-conserving surgery,3,4 with the caveat that neoadjuvant therapy is associated with an increase in locoregional recurrence (RR: 1.22; 95% CI: 1.04 to 1.43), especially in younger women (in whom tamoxifen was not given at the time that the trial was conducted) and in women for whom a mastectomy was initially proposed but was changed to breast-conserving surgery after neoadjuvant chemotherapy 2. Second, given that a pathologic complete response (pCR) is a surrogate marker for improved clinical outcome,2 neoadjuvant therapy provides an opportunity to undertake correlative research by allowing in vivo assessment of tumour response to particular drug regimens3. Lastly, from a practical viewpoint, neoadjuvant therapy allows patients to start treatment earlier if surgical wait times are too long. Neoadjuvant therapy also has its disadvantages, however. First, there is about a 5% chance that tumour progression may occur during neoadjuvant treatment, thereby delaying definitive local therapy 4. In addition, neoadjuvant treatment prevents definitive pathologic staging.

Locally advanced breast cancer (LABC) and inflammatory breast cancer (IBC) are, by definition, inoperable, and neoadjuvant therapy is therefore the sole treatment option. Chia et al.5 and Anderson et al.6 both described LABC as stage III disease (excluding T4d tumours), with a heterogeneous clinical phenotype.
that ranges from neglected low-grade estrogen receptor (ER)–positive to rapidly progressing ER-negative breast cancer. On the other hand, **IBC (T4d)** appears to have a different epidemiology, is typically diagnosed at a younger age, and is generally associated with higher tumour grade, negative ER status, and increased angiogenesis and lymphangiogenesis; historically, **IBC** has a worse survival rate $^{5-8}$.

The human epidermal growth factor receptor 2 (**HER2**) is a transmembrane tyrosine kinase receptor protein that is part of the **HER** family of growth factor receptors (**HER1–HER4**). The **HER2** receptor is involved in cell–cell and cell–stroma communication primarily through signal transduction involving the Ras/mitogen-activated protein kinase pathway and the phosphoinositide 3 kinase (PI3K)/Akt pathway $^9$. These signals ultimately promote cell proliferation, survival, and motility. Amplification of the **HER2/neu** gene and resulting overexpression of the **HER2** protein occurs in approximately 15%–20% of invasive primary breast cancers $^{10,11}$. Compared with **HER2**-negative cancers, early-stage breast cancer with a **HER2** alteration is associated with more aggressive disease and a higher risk of relapse $^{12-16}$.

Trastuzumab is a monoclonal antibody that binds to the extracellular domain of **HER2**. Several mechanisms of action underlie the antitumour effects of trastuzumab. Trastuzumab blocks **HER2**-activated cell signalling, thereby reducing cell proliferation and restoring a capacity for apoptosis by inhibiting the PI3K/Akt pathway $^{17-19}$, which increases cellular sensitivity to chemotherapy and radiotherapy $^{20}$. Trastuzumab has been shown to inhibit **HER2**-regulated angiogenesis $^{17,21-23}$ and, in preclinical models, to recruit the immune system through antibody-dependent cellular cytotoxicity, triggering activation of natural killer cell–mediated apoptosis $^{24-28}$. Trastuzumab has also been shown to prevent the formation of p95HER2 (a truncated, active form of **HER2**), which may lead to inhibition of tumour development $^{17,27}$.

Trastuzumab is now the standard of care in the adjuvant setting. A meta-analysis $^{28}$ of the five randomized controlled trials in the adjuvant setting [North Central Cancer Treatment Group (**NCCCTG**) 9831, National Surgical Adjuvant Breast and Bowel Project (NSABP) B31, the Herceptin® Adjuvant (**HERA**) trial, the Finland Herceptin (FinHer) trial, and Breast Cancer International Research Group 006] $^{29-32}$ comparing chemotherapy plus trastuzumab with chemotherapy alone in **HER2**-positive disease observed a relative reduction in relapse of 47% (absolute reduction: 7.1%) and a relative reduction in mortality rate of 48% (absolute reduction: 2.5%) after a follow-up of 2–3 years.

The body of studies evaluating the use of **HER2**-targeted agents in neoadjuvant therapy for both primary operable and primary inoperable **HER2**-positive breast cancer is growing, and the present paper reviews the current evidence and outlines suggestions from a panel of Canadian oncologists about the neoadjuvant use of trastuzumab and other **HER2**-targeted agents.

### 2. DEVELOPMENT OF PANEL SUGGESTIONS

The authors of this paper met in Toronto for a 1-day conference in June 2008. The panel reviewed the results of the latest trials using trastuzumab and other **HER2**-targeted agents in the neoadjuvant, adjuvant, and metastatic disease settings. Based on trial information, suggestions for each setting were formulated. For neoadjuvant therapy, a draft manuscript reviewing the currently available data and outlining the suggestions from the panel was initially written by a medical writer (BW) and reviewed and revised by four panel members (JLe, MC, LP, SC). The final manuscript was reviewed and approved by the rest of the panel members (SD, JLa, JM, KIP, DR, ShV, SuV). Recent clinical trial results (available as of June 2009) were incorporated into the present document, and the conclusions discussed were updated as additional evidence became available.

Development of the Canadian advisory panel and the present manuscript were funded by an unrestricted educational grant from Hoffmann–La Roche Canada. The authors received an honorarium for attending the conference, but not for writing the manuscript. The authors are responsible for the content of the manuscript, with no restrictions set by the sponsor.

The panel focussed on

- the use of trastuzumab and other **HER2**-targeted agents as neoadjuvant therapy in primary operable, locally advanced, and inflammatory breast cancer; and
- possible choices of chemotherapeutic regimens with trastuzumab.

The related clinical evidence is presented and discussed below. Key panel suggestions are followed by a discussion of the supporting evidence, the panel’s rationale for the suggestions, and any points on which consensus was lacking.

### 3. NEOADJUVANT TRIALS USING TRASTUZUMAB

Two recently reported randomized controlled prospective trials comparing chemotherapy with and without **HER2**-targeted therapy in the neoadjuvant setting (Table 1) are reviewed here.

#### 3.1 MD Anderson Trial

In a small, two-arm, phase III randomized prospective trial, Buzdar et al. compared 225 mg/m$^2$ paclitaxel


| Reference                     | Treatment                              | Patients (n) | Pathologic CR [% (95% CI)] | DFS [% (95% CI)] |
|-------------------------------|----------------------------------------|--------------|----------------------------|-----------------|
|                               |                                        |              | H arm                      | Non-H arm       |
|                               |                                        |              |                            |                 |
| Buzdar et al., 2005           | H + (P→FEC) VS. P→FEC (stage IIIB)    | 42           | 65.2 (43–84)               | 26.3 (9–51)     |
| (MD Anderson trial)           |                                        |              | p=0.016                    |                 |
| Buzdar et al., 2007           |                                        | 64           | 60.0 (44.3–74.3)           | 26.3 (9–51)     |
| (MD Anderson trial update)    |                                        |              | 100 (85.2–100)             | 85.3 (67.6–100) |
|                               |                                        |              | p value not reported       |                 |
|                               |                                        |              | 100 (92–100)               | 94.7 (85.2-100) |
| Gianni et al., 2008           | H + (AP→P→CMF) →surgery→H VS. AP→P→CMF→surgery | 227         | 43                         | 23              |
| NOAH trial                    |                                        |              | p=0.002                    |                 |
|                               |                                        |              | 70.1                       | 53.3            |
|                               |                                        |              | p=0.006                    |                 |
|                               |                                        |              | hr: 0.56                   |                 |
| Baselga et al., 2007          |                                        | 61           | 55                         | 19              |
| [NOAH trial (HER2+IBC)]       |                                        |              | p=0.004                    |                 |

---

**a** Combined values, includes additional patients.

**b** 3-Year follow-up, does not include additional patients (n = 42).

**c** 1-Year follow-up, including additional patients.

**d** Overall survival data not yet mature. Preliminary results show 17 events in the H arm and 22 events in the non-H arm. There is a positive trend for the H arm at a median follow-up of 3 years: p = 0.18; hazard ratio: 0.65.

**e** 3-Year median follow-up.

**f** Presented as event-free survival, defined by either progression on therapy or relapse after surgery or death from any cause.

CR = complete response; CI = confidence interval; DFS = disease-free survival; P = paclitaxel; FEC = 5-fluorouracil, epirubicin, cyclophosphamide; AP = doxorubicin, paclitaxel; CMF = cyclophosphamide, methotrexate, 5-fluorouracil; HR = hazard ratio; IBC = inflammatory breast cancer.
in a 24-hour continuous intravenous infusion every 3 weeks for 4 cycles, followed by FEC [500 mg/m² 5-fluorouracil (5FU) on days 1 and 4, 75 mg/m² epirubicin on day 1, 500 mg/m² cyclophosphamide on day 1] every 3 weeks for 4 cycles as neoadjuvant therapy without (p→FEC) and with [H+(p→FEC)] concurrent trastuzumab (4 mg/kg loading dose on day 1) of the first treatment cycle before paclitaxel, and 2 mg/kg maintenance dose weekly for 24 doses)³. The study accrued 42 patients with histologically confirmed invasive, but noninflammatory, stage II–III A carcinoma of the breast. The primary objective was to demonstrate a doubled improvement in PCR—defined as no evidence of residual invasive cancer in both breast and axilla—with the addition of trastuzumab to chemotherapy. The trastuzumab-based treatment arm displayed a PCR improvement by a factor of 2.5 relative to chemotherapy alone (65.2% vs. 26.3%, p = 0.016). As a result of the superior response attributed to trastuzumab, the data analysis was presented to the MD Anderson Data Monitoring Committee. Based on recommendations by that committee, the protocol of the original study was changed to discontinue the chemotherapy-alone arm. Recruitment was continued in the H+(p→FEC) arm only. A total of 45 patients received the H+(p→FEC) regimen. The PCR rate for the updated combined trastuzumab treatment arm (n = 45) was also superior to chemotherapy alone (60% vs. 26.3%; 95% CI: 44.3% to 74.3%; Table 1)³. Notably, trastuzumab was given concomitantly with epirubicin. The median left ventricular ejection fraction (LVEF) was 65% at baseline in the both trial arms; after 6 months, the median LVEF was 65% (range: 55%–70%) in the (p→FEC) arm, but 60% (range: 52%–70%) in the H+(p→FEC) arm. No clinical cardiac dysfunction was reported; however, the sample size was small, and the follow-up duration was short.

3.2 Neoadjuvant Herceptin Trial

The international multicentre phase III randomized NOAH (Neoadjuvant Herceptin) trial compared the efficacy of doxorubicin (60 mg/m²) and paclitaxel (150 mg/m²) every 3 weeks for 3 cycles, followed by paclitaxel alone (175 mg/m²) every 3 weeks for 4 cycles, followed by cyclophosphamide (600 mg/m²), methotrexate (40 mg/m²), and 5FU (600 mg/m²) every 4 weeks on days 1 and 8 for 4 cycles without (AP→CMF) and with [H+(AP→CMF)] concurrent trastuzumab [8 mg/kg loading dose, then 6 mg/kg every 3 weeks (concurrent with cycle 1 onward) continued to 52 weeks] as first-line therapy in patients with HER2-overexpressing LABC (including IBC)³. A HER2-negative third arm was also accrued as reference for the HER2-overexpressing arms, but these patients were not given trastuzumab. Data presented here refer to the group of HER2-positive patients (trastuzumab arm vs. no trastuzumab arm).

The primary endpoint was event-free survival (EFS), which was defined as progression on therapy, relapse after surgery, or death from any cause. The secondary endpoints were PCR rate, overall survival, and safety and tolerability. In both HER2-positive arms (with and without trastuzumab), 42%–43% of the patients presented with T4 noninflammatory breast cancer, 27% presented with IBC, and 30%–31% presented with N2 disease. In the intention-to-treat population (n = 227), patients receiving trastuzumab (n = 115) experienced a significantly improved 3-year EFS rate relative to chemotherapy alone [70.1% vs. 53.3%; hazard ratio (HR): 0.56; 95% CI: 0.36 to 0.85; p = 0.006; Table 1].

In addition, the PCR rate was significantly higher in the trastuzumab-containing treatment arm (43% vs. 23%, p = 0.002), and a trend toward improved overall survival was observed (HR: 0.65; 95% CI: 0.34 to 1.23; p = 0.18)³⁴. The rate of breast-conserving surgery nearly doubled in the trastuzumab arm (23% vs. 12.5%, p = 0.07)³⁶. In the subgroup of patients with HER2-positive IBC (n = 61), the addition of trastuzumab to chemotherapy also significantly improved PCR (55% vs. 19%, p = 0.004) and total PCR (48% vs. 13%, p = 0.002)³⁵.

Neoadjuvant trastuzumab was well tolerated with reasonable cardiac safety. Only a 2.1% cumulative incidence of New York Heart Association (NYHA) grade 3 congestive heart failure (CHF) was observed in the trastuzumab arm³⁴ even though trastuzumab was delivered concurrently with doxorubicin (60 mg/m²) and paclitaxel (150 mg/m²). In contrast, the non-trastuzumab-containing group in HER2-positive patients and the HER2-negative group both reported no incidence of NYHA grade 3 CHF.

Although this study is very interesting, to date it has been published only in abstract form. No other randomized trials have compared trastuzumab with no trastuzumab treatment. However, a number of other ongoing trials have included trastuzumab as part of the treatment arm in the HER2-overexpressing cohort.

The two trials presented next included concomitant (GeparQuattro) or sequential (TECHNO) anthracyclines and trastuzumab.

3.3 GeparQuattro Trial

A multicentre prospective randomized three-arm trial studied the possible benefits of adding capecitabine, either concomitantly or sequentially, to docetaxel after 4 cycles of epirubicin (90 mg/m²) and cyclophosphamide (600 mg/m²)³⁷ (EC). Patients with HER2-positive breast cancer received trastuzumab for 1 year, starting with EC in all three arms, thereby collecting data on the cardiac safety of trastuzumab and anthracyclines given concomitantly. Results presented in an abstract form showed only that neoadjuvant trastuzumab was well tolerated, with no cases of grade 4 congestive heart failure. No patients
showed a decrease in LVEF to below 45%. The pCR rate in a combined analysis of all three HER2-positive treatment arms treated with concurrent trastuzumab was 45%. Investigators concluded that the addition of trastuzumab to chemotherapy was feasible without clinically relevant cardiotoxicity.

3.4 Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant Trial

The multicentre phase II single-arm Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO) trial (NCT00795899) examined the safety and efficacy of epirubicin (90 mg/m²) and cyclophosphamide (600 mg/m²) every 3 weeks for 4 cycles, followed by trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg) and paclitaxel (175 mg/m²) every 3 weeks for 4 cycles as neoadjuvant therapy in patients with HER2-positive primary breast cancer >2 cm or inflammatory disease. After surgery, patients continued trastuzumab (6 mg/kg) every 3 weeks for 12 cycles. The primary clinical endpoints were histopathologic response rates (breast and axilla) and overall cardiac toxicity; secondary endpoints were disease-free survival, overall survival, rate of breast conservation, and quality of life. This trial has been completed. In an abstract presented in 2006, the pCR rate was 20%.

4. NEOADJUVANT TRIALS USING LAPATINIB

Recently, Migliaccio et al. performed two sequential single-arm neoadjuvant clinical trials in HER2-overexpressing LABC patients to compare the clinical efficacy and mechanism of action of trastuzumab with those of lapatinib, an oral epidermal growth factor receptor/HER2 tyrosine kinase inhibitor. Patients in the single-arm trastuzumab trial were given a standard trastuzumab dose for the first 3 weeks followed by trastuzumab and standard docetaxel every 3 weeks for 12 weeks (n = 35). Patients in the lapatinib single-arm trial were given 1500 mg oral lapatinib daily for 6 weeks followed by trastuzumab and standard docetaxel every 3 weeks for 12 weeks (n = 49). Clinical efficacy of the trial that gave initial trastuzumab, as determined by the pCR rate (defined here as the complete disappearance of all invasive cancer or minute foci of residual disease (<0.5 cm) in breast), was 34% (11/32) as compared with 68% (23/34) in the trial that gave initial lapatinib. It must be noted that, because both trials used trastuzumab with docetaxel, the lapatinib trial was not a lapatinib-only design. Further study results showed that tumours with low PTEN predicted resistance to trastuzumab.

5. FUTURE STUDIES

Using www.clinicaltrials.gov, we found 14 randomized clinical trials for HER2-positive breast cancer in the neoadjuvant setting (Table I). Most of these trials used pCR as the primary endpoint.

Eight trials compared trastuzumab with lapatinib or a combination of both agents. One trial (NeoSphere) is currently examining the safety and efficacy of the various combinations of trastuzumab and pertuzumab, another monoclonal antibody that targets HER2, in the presence or absence of chemotherapy for LABC or IBC. As a complement to trastuzumab, pertuzumab inhibits the HER2-mediated signalling pathway by binding to a different epitope on the HER2 extracellular domain, thereby preventing HER2 dimerization with other members of the HER2 family. In vitro evidence suggests that these two agents act synergistically to inhibit the survival of breast cancer cells, suggesting that the combination of these two agents would be a more effective therapeutic strategy.

The American College of Surgeons Oncology Group (ACOSOG) Z1041 trial is examining the sequence of FEC75–paclitaxel plus trastuzumab, in which FEC75 is given either before or after the paclitaxel and trastuzumab. Other trials are testing new agents such as everolimus.

The German Breast Group 44 trial (GeparQuinto) will randomize 2547 patients to six arms: one without neoadjuvant targeted therapy, one with bevacizumab, one with only trastuzumab and no chemotherapy, one with everolimus, one with chemotherapy plus trastuzumab, and one with chemotherapy plus lapatinib. These large clinical trials may answer many clinical questions, such as “Is it better to give a combination of targeted agents rather than one agent?”

6. PANEL SUGGESTIONS FOR TREATMENT IN NEOADJUVANT THERAPY

6.1 HER2-Targeted Agents as Neoadjuvant Therapy in HER2-Positive Primary Operable LABC or IBC

Suggestion: Currently, the panel felt that trastuzumab is standard in the neoadjuvant setting in combination with chemotherapy in patients with HER2-overexpressing breast cancer when a clinical decision has been made to treat with neoadjuvant chemotherapy. Other HER2-targeting agents such as lapatinib and pertuzumab should be given only as part of a clinical trial.

Discussion: The addition of trastuzumab in neoadjuvant systemic therapy clearly increases pCR in primary operable breast cancer, and a growing body of clinical evidence shows a similar result in LABC and IBC. Furthermore, increased pCR after preoperative therapy has been shown to be a surrogate marker for long-term disease-free survival and overall survival in some trials. However, in the NSABP B27 trial, despite increased pCR, no survival advantage was shown with the addition of docetaxel.
to an anthracycline-based regimen. Investigation of new agents in combination with conventional systemic therapies in the preoperative or neoadjuvant setting can provide tissue sampling to assess markers of in vivo tumour responses. As well, pCR can be used as a surrogate, allowing for testing of new interventions in smaller phase II trials before they are studied in larger phase III clinical trials, which require a larger sample size and longer follow-up.

The latest and strongest evidence relies on the final study results of the NOAH trial. Here, the addition of trastuzumab to chemotherapy in HER2-positive patients significantly improved event-free survival at 3 years relative to chemotherapy alone (70.1% vs.

| Trial name            | Type   | Treatment                                                                 | Expected accrual | Estimated completion date |
|-----------------------|--------|---------------------------------------------------------------------------|------------------|---------------------------|
| ACOSOG-Z1041(NCT00513292) | Phase III | FEC75→TH vs. TH→FEC75 + H vs. chemotherapy + H vs. chemotherapy + LH | 270              | June 2008                 |
| EGF106988 (NCT00429299)  | Phase II | Chemotherapy + L vs. chemotherapy + H vs. chemotherapy + LH              | 120              | June 2009                 |
| 03–311 (NCT00148668)   | Phase II | H + vinorelbine vs. DCxH vs. H→HT vs. H→HT                               | 81               | December 2009             |
| NeoALTTO (NCT00553358) | Phase III | LH→LHT vs. L→LT vs. H→HT                                                 | 450              | April 2010                |
| CALGB-40601 (NCT00770809) | Phase III | H + T + L vs. H + T vs. T + L                                            | 400              | June 2010                 |
| NSABP B-41 (NCT00486668) | Phase III | AC→TH vs. AC→TL vs. AC→THL                                                | 522              | July 2010                 |
| GSK-LAP107087 (NCT00499681) | Phase II | L + letrozole vs. placebo + letrozole                                      | 36               | July 2010                 |
| 1200.44 (NCT00826267)   | Phase II | BIBW 2992 vs. L vs. H                                                     | 120              | December 2010             |
| GBG 44 (NCT00567554)    | Phase III | EC→D vs. EC→D + B vs. T vs. T + everolimus vs. EC→DH vs. EC→DL = EC→D + L vs. EC→D + H | 2547             | December 2010             |
| GEOCAM/2006-14 (NCT00841828) | Phase II | H vs. H + everolimus vs. EC→D + H                                          | 102              | December 2011             |
| EU-20851 (NCT00674414)   | Phase II | H vs. H + everolimus vs. EC→D + H                                         | 120              | April 2014                |
| NeoSphere (NCT00545688)  | Phase II | H + D vs. H + P + D vs. H + P vs. P + D                                   | 400              | August 2014               |
| H-20464 (NCT00548184)    | Phase II | HL vs. HL + endocrine therapy                                             | 64               | January 2015              |
| LPT109096 (NCT00524303)  | Phase II | FEC75→TH vs. FEC75→TH                                                   | 99               | Not available             |

f = 5-fluorouracil; e = epirubicin; c = cyclophosphamide; t = paclitaxel; h = trastuzumab; l = lapatinib; d = docetaxel; cb = carboplatin; a = doxorubicin; b = bevacizumab; p = pertuzumab.
53.3%; HR: 0.56; 95% CI: 0.36 to 0.85; p = 0.006), with an overall survival trend (HR: 0.65; 95% CI: 0.34 to 1.23; p = 0.18)\textsuperscript{34}. The HR and absolute benefit for the addition of trastuzumab are in the range seen during the large adjuvant trials with trastuzumab; however, these results were delivered with a much smaller number of patients (n = 227 vs. n > 13,000). The acceptable cardiac safety data also show that it may be reasonable to use a low cumulative dose of anthracycline concurrently with trastuzumab. Altogether, the noah trial has demonstrated that neoadjuvant trastuzumab for 1 year in combination with chemotherapy is a standard of care for women with \textit{labc} of \textit{ibc} \textit{her2}-positive breast cancer. Publication of final results is eagerly awaited.

No trial has tested, or is testing, the effect of starting trastuzumab in the neoadjuvant setting against starting it after surgery. The ncctg 9831 trial has examined the benefits of trastuzumab concurrent with chemotherapy versus trastuzumab sequential after chemotherapy. Results of the data analysis are pending. In regard to duration, based on the adjuvant trials, total duration is 1 year at present. Studies to determine if a 6-month treatment is equivalent to a 12-month treatment (NCt00712140, NCT00615602) or if 2 years’ treatment provides further benefits over 1 year’s treatment (HERA) are ongoing. In Finland, a trial is also comparing 9 weeks with 51 weeks of adjuvant trastuzumab (NCT00593697).

### 6.2 Possible Combination Regimens with Trastuzumab

**Suggestion:** Currently, the panel felt that concurrent trastuzumab with the taxane component of commonly-used neoadjuvant regimens is a reasonable standard in primary operable, locally advanced, or inflammatory breast cancer. However, current data are not strong enough to support the concurrent use of trastuzumab with anthracyclines, given the potential cardiac toxicity.

**Discussion:** The panel noted that no randomized trials were available in \textit{labc} or \textit{ibc} to support any particular trastuzumab-based regimen. Several published regimens included concurrent anthracyclines with trastuzumab\textsuperscript{3,33,34,36}, but caution is needed in using this approach because the overall sample size in these studies is small, the patient populations were highly selected, and the primary aim was not the cardiac safety of trastuzumab treatment given concurrently with anthracyclines. Also, the follow-up for cardiotoxicity was only short-term. It must be noted that the total dose of anthracyclines was lower than that usually given in the adjuvant setting, and the risk–benefit ratio of these regimens is not fully defined. Long-term follow-up and randomized comparisons of the regimens will be required for definitive recommendations. In the HERA trial, higher cumulative doses of anthracyclines were found to contribute as a risk factor for trastuzumab-associated cardiotoxicity\textsuperscript{42}. Although the population benefiting from anthracyclines is that with \textit{TOPO2A} gene alterations, found mainly in \textit{her2}-positive breast cancers\textsuperscript{33}, no evidence supports concurrent anthracycline and trastuzumab in the adjuvant setting. In the metastatic setting, anthracyclines given concurrently have been shown to be associated with an unacceptable rate of cardiac toxicity, and therefore the combination is contraindicated in that setting\textsuperscript{44}.

In the context of primary operable breast cancer, in which patients seek a better chance for breast conservation, the panel agreed that all adjuvant data could be extrapolated to neoadjuvant therapy for clinical benefit, but with a higher chance of breast conservation. In the context of \textit{labc} and \textit{ibc}, there is increasing evidence that \textit{her2}-targeted strategies used in the adjuvant setting may be applicable in the neoadjuvant setting. Data from the two randomized controlled trials of trastuzumab versus no trastuzumab in operable breast cancer (MD Anderson Trial) or in \textit{labc} and \textit{ibc} (noah trial) showed that trastuzumab is associated with a significant increase in PCR. In the absence of data from randomized trials comparing neoadjuvant with adjuvant trastuzumab, the panel felt that initiating trastuzumab preoperatively and continuing it postoperatively for 1 year in total is reasonable. In an ongoing phase III trial in \textit{her2}-positive breast cancer (Neo-Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation), the total duration of \textit{her2}-targeted therapy is also 1 year.

Whether trastuzumab should be given concurrently with chemotherapy or after chemotherapy remains an open question. Answers will be obtained with the analysis of the ncctg 9831 trial in which trastuzumab was given concurrently with paclitaxel in one arm and trastuzumab was given sequentially in another arm in the adjuvant setting.

The transfer to the neoadjuvant setting of regimens proven efficacious in the adjuvant setting is supported by a meta-analysis\textsuperscript{1}. Although the regimens used were mainly doxorubicin and cyclophosphamide (AC), FAC, and FEC\textsubscript{60}, it is reasonable to believe that other chemotherapy regimens would be as efficacious if given preoperatively compared with postoperatively. However, the optimal duration of chemotherapy is unknown. For example, the preliminary results of the NSABP 30 trial in operable breast cancer showed that 8 cycles of chemotherapy (AC followed by docetaxel) were superior to 4 cycles of doxorubicin and docetaxel or of docetaxel, doxorubicin, and cyclophosphamide\textsuperscript{45}.

Although the efficacy results are quite convincing, the panel warned that a decision to give concurrent neoadjuvant anthracyclines with trastuzumab could not be made based on the neoadjuvant trials conducted to date. More studies and longer follow-up from the aforementioned trials, with particular atten-
tion to cardiac effects, are required to provide further insight into the cardiac safety of such combinations.

7. CONCLUSIONS

Trastuzumab has become a standard of care in the adjuvant and metastatic settings for patients with HER2-positive breast cancer. The evolving data in the neoadjuvant setting suggest that the addition of trastuzumab to neoadjuvant systemic therapy significantly increases pCR, breast conservation rates, and event-free survival. A strategy of concurrent anthracyclines with trastuzumab appears promising, possibly further maximizing the efficacy of trastuzumab in high-risk patient populations. However, the cardiotoxicity risk (although relatively low so far) continues to be a concern. The present article provided panel suggestions based on available data about the use of trastuzumab preoperatively. The suggestions set out here will continue to evolve as data and experience here will continue to evolve as data and experience with trastuzumab and other HER2-targeted agents in trials of neoadjuvant systemic therapy emerge.

8. DATE OF PANEL SUGGESTIONS

Panel suggestions were completed in June 2009.

9. REFERENCES

1. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005;97:188–94.
2. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;(30):96–102.
3. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2–positive operable breast cancer. J Clin Oncol 2005;23:3676–85.
4. von Minckwitz G, Kümmler S, Vogel P, et al. Neoadjuvant vinorelbine–capecitabine versus docetaxel–doxorubicin–cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008;100:542–51.
5. Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. J Clin Oncol 2008;26:786–90.
6. Anderson WF, Chu KC, Chang S. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol 2003;21:2254–9.
7. McCarthy NJ, Yang X, Linnoila IR, et al. MicrovesSEL density, expression of estrogen receptor alpha, miR-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 2002;8:3857–62.
8. Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2000;2:423–9.
9. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antiumor action. Cancer Res 2002;62:4132–41.
10. Quénel N, Wafflard J, Bonichon F, et al. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 1995;35:283–91.
11. Konceny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142–53.
12. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–82.
13. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–12.
14. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Natl Cancer Inst 1992;10:1049–56.
15. Hynes NE, Stern DF. The biology of erbB-2/neu and its role in cancer. Biochim Biophys Acta 1994;1198:165–84.
16. Choi YH, Ahn JH, Kim SB, et al. Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis. Ann Oncol 2009;20:1337–43.
17. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006;232:123–38.
18. Longva KE, Pedersen NM, Haslekås C, Stang E, Madshus IH. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 2005;116:359–67.
19. Migliacchio I, Gutierrez MC, Wu MF, et al. m3 kinase activation and response to trastuzumab or lapatinib in HER2-overexpressing locally advanced breast cancer (LABC). Presented at the 31st Annual San Antonio Breast Cancer Symposium; San Antonio, TX, U.S.A.; December 10–14, 2008. [Available online at: www.abstracts2view.com/sabs/view. php?nu=SABC08L_1226&term=; cited August 13, 2009]
20. Pegram MD, Konceny GE, O’Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739–49.
21. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 2002;416:279–80.
22. Wen XF, Yang G, Mao W, et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006;25:6986–96.
23. Klos KS, Zhou X, Lee S, et al. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2–mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 2003;98:1377–85.
24. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6:443–6.
25. Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004;10:5650–5.
26. Arnould L, Gelly M, Penault–Llorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006;94:259–67.
27. Molina MA, Codony–Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;61:4744–9.
28. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of HER2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007;7:153.
29. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–84.
30. Piccart–Gebhart MJ, Proctor M, Leyland–Jones B, et al. on behalf of the Herceptin Adjuvant (HERA) trial study team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–72.
31. Joensuu H, Kellokumpu–Lehtinen PL, Bono P, et al. on behalf of the FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809–20.
32. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide with doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-neu positive early breast cancer patients. Presented at the 29th Annual San Antonio Breast Cancer Symposium; San Antonio, TX, U.S.A.; December 14–17, 2006. [Available online at: www.abstracts2view.com/sabcs06/view.php?n=SABCS06L_78&terms=; cited August 13, 2009]
33. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluourouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13:228–33.
34. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. Presented at the 31st Annual San Antonio Breast Cancer Symposium; San Antonio, TX, U.S.A.; December 10–14, 2008. [Available online at: www.abstracts2view.com/sabcs/view.php?n=SABCS08L_1443&terms=; cited August 13, 2009]
35. Baselga J, Semiglazov V, Manikhas GM, et al. Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from the NOAH (Neoadjuvant Herceptin) phase III trial [abstract 2030]. Eur J Cancer 2007;5:193.
36. Semiglazov V, Eiermann W, Manikhas A, et al. Surgical aspect in NOAH phase III trial (neoadjuvant trastuzumab in HER2-positive locally advanced breast cancer). Eur J Cancer Suppl 2008;6:169–70.
37. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBO/AGO multicenter intergroup-study “GeparQuattro” [abstract 1LB]. Eur J Cancer Suppl 2008;6:47. [Presented at the 6th European Breast Cancer Conference; Berlin, Germany; April 15–19, 2008]
38. Untch M, Stoeckl D, Konecny G, et al. A multicenter phase II study of preoperative epirubicin, cyclophosphamide (EC) followed by paclitaxel (P) plus trastuzumab (T) in HER2 positive primary breast cancer [abstract 1064]. Breast Cancer Res Treat 2005:94:60–1.
39. Ruehl IM, Wirtz RM, Lenhard M, et al. Significance of cyclin D1 expression and amplification status in paraffin-embedded tissue of HER2/neu positive breast cancer patients treated in a neoadjuvant trastuzumab-containing protocol (TECHNO-trial). Presented at the 29th Annual San Antonio Breast Cancer Symposium; San Antonio, TX, U.S.A.; December 14–17, 2006. [Available online at: www.abstracts2view.com/sabcs06/view.php?n=SABCS06L_1052&terms=; cited August 13, 2009]
40. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127–37.
41. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64:2343–6.
42. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab–associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol 2007;25:3859–65.
43. O’Malley FP, Chia S, Tu D, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009;101:644–50.
44. Slamon DJ, Leyland–Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–92.
45. Swain SM, Jeong JH, Geyer CE, et al. NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. Presented at the 31st Annual San Antonio Breast Cancer Symposium; San Antonio, TX, U.S.A.; December 10–14, 2008. [Available online at: www.abstracts2view.com/sabcs/view.php?n=SABCS08L_1017&terms=; cited August 13, 2009]

Correspondence to: Julie Lemieux, Unité de recherche en santé des populations, Centre de Recherche du Centre Hospitalier affilié universitaire de Québec, 1050 chemin Ste-Foy, Local JS1-01, Quebec City, Quebec G1S 4L8. E-mail: julie.lemieux@uresp.ulaval.ca
* Unité de recherche en santé des populations, Centre de Recherche du Centre Hospitalier affilié universitaire de Québec, Quebec City, QC.
† Hôpital du Saint-Sacrement, Quebec City, QC.
‡ Princess Margaret Hospital, Toronto, ON.
§ Ottawa Hospital Cancer Centre, Ottawa, ON.
|| Centre Intégré de cancérologie de la Montérégie and Réseau Cancer Montérégie, Longueuil, QC.

# Cross Cancer Institute, Edmonton, AB.
** Sunnybrook Odette Cancer Centre, Toronto, ON.
†† Atlantic Clinical Cancer Research Unit and QEII Health Sciences Centre, Halifax, NS.
‡‡ Remedy Communications Limited, Toronto, ON.
§§ British Columbia Cancer Agency–Vancouver Centre, Vancouver, BC.